La cadena de opciones muestra datos clave de las opciones de acciones de Forza X1 a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Forza X1..

Forza X1 (OTC:FRZA) Bolsa, Cadena de Opciones

Forza X1

Forza X1 Inc develops and manufactures fully electric, affordable boats with mass appeal. The company is focused on the creation, implementation, and sale of electric boats utilizing its electric vehicle (EV) technology to control and power its boats and proprietary outboard electric motor. its electric boats are being designed as fully integrated electric boats including the hull, outboard motor, and control system. Its initial two models, the FX1 Dual Console and FX1 Center Console are being designed to be 24 feet in length, have an 8' beam or width, and utilize a catamaran hull surface to reduce drag and increase run times.

Forza X1 Inc

News

Merck Announced That Health Canada Approved Keytruda (Pembrolizumab), Merck's Anti-PD-1 Therapy, In Combination With Carboplatin And Paclitaxel, Followed By Keytruda As A Single Agent, For The Treatment Of Adult Patients With Primary Advanced Or Recurrent Endometrial Carcinoma

Upon closing, the acquisition will provide a number of key benefits: &nbsp; &nbsp;
<ul>
<li>Enhances margins: Immediately accretive to Sportradar's adjusted EBITDA margins, aligning with our disciplined investment approach;&nbsp;</li>
<li>Accelerates growth: Further accelerates Sportradar's robust revenue, adjusted EBITDA and cash flow growth;&nbsp;&nbsp;</li>
<li>Unique structure: Sportradar will not be required to pay any financial consideration; Transaction provides financial consideration totaling $225 million comprised of $125 million paid to Sportradar and up to $100 million cash prepayments made by Endeavor to certain of the sports rightsholders; &nbsp;</li>
<li>Highly strategic portfolio: Basketball, soccer and tennis account for approximately 70% of the rights which are the top three most bet on global sports, complementing our existing sports portfolio.&nbsp;</li>
</ul>

SRAD

Sportradar To Acquire IMG ARENA And Its Global Sports Betting Rights For $225M, Deal Expected to Close in Q4 2025

Guidance

General Mills Expects FY25 Organic Net Sales To Be Down 2% - Down 1.5% Vs Previous Expectation Of Lower End Of Flat - Up 1% Range

HC Wainwright &amp; Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) with a Buy and lowers the price target from $9 to $8.

Price Target

Analyst Ratings

ALLO

HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $8

Biotech

General

BDTX

Black Diamond Therapeutics And Servier Announce A Global Licensing Agreement For BDTX-4933 For Solid tumors; Servier Will Develop And Commercialize BDTX-4933, Black Diamond To Receive $70M Upfront Payment And Up To $710M In Milestones

FINANCIAL GUIDANCE
HUTCHMED provides full year 2025 guidance for Oncology/Immunology consolidated revenue of $350 million to $450 million. HUTCHMED's work in 2025 and beyond will be supported by its strong balance sheet. The Company will continue to be financially self-reliant while supporting investments to bring innovative medicines to patients globally.

Earnings

HUTCHMED Projects 2025 Oncology Revenue Between $350M–$450M, Backed By Strong Balance Sheet

ALTR

NVDA

Altair Announced A Technical Integration Between The NVIDIA Omniverse Blueprint For Real Time Digital Twins And The Altair One Cloud Innovation Gateway

Health Care

MDWD

MediWound Expects 2025 Sales Of $25M Versus Consensus Of $24.98M

AEVA

Aeva Announced That A Global Top 10 Passenger OEM Has Awarded Aeva A Development Program For Its Next-generation Global Vehicle Platform

In addition, the company plans to make investments in the fourth quarter in advance of significant fiscal 2026 new product launches

General Mills Expects Macroeconomic Uncertainty To Continue To Impact Consumers In Q4

Signet Jewelers Sees FY26 Adj EPS Of $7.31 - $9.10 Vs. $9.00 Est.

HUTCHMED (China) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) reported quarterly earnings of $0.22 per share. This is a 62.07 percent decrease over earnings of $0.58 per share from the same period last year. The company reported $630.20 million in sales this quarter. This is a 24.80 percent decrease over sales of $838.00 million the same period last year.

HUTCHMED (China) FY 2024 GAAP EPS $0.22 Down From $0.58 YoY, Sales $630.20M Down From $838.00M YoY

HC Wainwright &amp; Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) with a Buy and maintains $10 price target.

Reiteration

CATX

HC Wainwright & Co. Reiterates Buy on Perspective Therapeutics, Maintains $10 Price Target

CABA

Cellares, The First Integrated Development And Manufacturing Organization (IDMO), Has Concluded The Technology Adoption Program (TAP) On Its Automated Cell Therapy Manufacturing Cell Shuttle For Resecabtagene Autoleucel, (Rese-cel, Previously Known As CABA-201)

Signet Jewelers Sees FY26 Sales Of $6.53B - $6.80B Vs. $6.724B Est; FY26 Adjusted EBITDA Of $605M - $695M

AVIR

Atea Pharmaceuticals Announced The Poster Presentation Of Bemnifosbuvir Preclinical Data At The 38Th International Conference On Antiviral Research 2025 Taking Place March 17-21, 2025 In Las Vegas, Nevada

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.59) by 38.98 percent. This is a 89.47 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $5.84 million which beat the analyst consensus estimate of $5.75 million by 1.60 percent. This is a 9.40 percent increase over sales of $5.34 million the same period last year.

MediWound Q4 2024 GAAP EPS $(0.36) Beats $(0.59) Estimate, Sales $5.84M Beat $5.75M Estimate

Outlook
For the first quarter of fiscal 2025, the Company expects:
<ul>
<li>Net sales to decline 1% to 4% compared to the first quarter of fiscal 2024</li>
<li>Comparable Sales to decline 2% to 5% compared to the first quarter of fiscal 2024</li>
<li>Adjusted EBITDA to be in the range of $25.0 million to $27.0 million</li>
</ul>

JILL

J.Jill Q1 Outlook: Sales Decline Of 1%-4% To $155.052M-$159.898M vs $165.22M Est

General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) reported quarterly earnings of $1.00 per share which beat the analyst consensus estimate of $0.96 by 4.17 percent. This is a 14.53 percent decrease over earnings of $1.17 per share from the same period last year. The company reported quarterly sales of $4.84 billion which missed the analyst consensus estimate of $4.96 billion by 2.41 percent. This is a 5.04 percent decrease over sales of $5.10 billion the same period last year.

Earnings Beats

Earnings Misses

General Mills Q3 2025 Adj EPS $1.00 Beats $0.96 Estimate, Sales $4.84B Miss $4.96B Estimate

Signet Jewelers Sees Q1 Sales Of $1.50B - $1.53B Vs. $1.504B Est; Adj EBITDA Of $94M - $106M

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, FRZA, TTNP on Behalf of Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, TTNP, FRZA on Behalf of Shareholders

Kuehn Law Encourages EVBN, ITI, FRZA, and SDIG Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FYBR, BTTR, GATO, FRZA on Behalf of Shareholders

Kuehn Law Encourages FRZA, AG, ITI, and FLIC Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLIC, ITI, AG, FRZA on Behalf of Shareholders

FORZA X1 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forza X1, Inc. - FRZA

Penny Stocks

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Looming Votes of FRZA and VEEE

Sports

Twin Vee PowerCats Co. and Forza X1, Inc. Shareholders Vote to Approve Merger Between Companies

Comments

Forza X1

Forza X1 (FRZA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL